Device design modifications informed by in vitro testing of bacterial attachment reduce infection rates of cochlear implants in clinical practice by Turnbull, Lynne et al.
microorganisms
Article
Device Design Modifications Informed by In Vitro Testing of
Bacterial Attachment Reduce Infection Rates of Cochlear
Implants in Clinical Practice
Lynne Turnbull 1, Roger Leigh 2, Rosalia Cavaliere 1 , Sarah R. Osvath 1, Laura M. Nolan 3, Daniel Smyth 2,
Kristien Verhoeven 2, Richard A. Chole 4 and Cynthia B. Whitchurch 1,5,6,*


Citation: Turnbull, L.; Leigh, R.;
Cavaliere, R.; Osvath, S.R.;
Nolan, L.M.; Smyth, D.; Verhoeven, K.;
Chole, R.A.; Whitchurch, C.B. Device
Design Modifications Informed by In
Vitro Testing of Bacterial Attachment
Reduce Infection Rates of Cochlear
Implants in Clinical Practice.
Microorganisms 2021, 9, 1809.
https://doi.org/10.3390/
microorganisms9091809
Academic Editor: Ute Römling
Received: 15 April 2021
Accepted: 20 August 2021
Published: 25 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 The iThree Institute, University of Technology Sydney, Ultimo, NSW 2007, Australia;
Lynne.Turnbull@leica-devices.com (L.T.); rosalia.cavaliere@uts.edu.au (R.C.);
Sarah.Osvath@uts.edu.au (S.R.O.)
2 Cochlear Limited, 1 University Avenue, Macquarie University, Sydney, NSW 2109, Australia;
rleigh@cochlear.com (R.L.); dsmyth@cochlear.com (D.S.); kverhoeven@cochlear.com (K.V.)
3 National Heart and Lung Institute, Imperial College London, London SW3 6LR, UK; l.nolan@imperial.ac.uk
4 Washington School of Medicine in St Louis, Washington University in St. Louis, St. Louis, MO 63110, USA;
rchole@wustl.edu
5 Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK
6 School of Biological Sciences, University of East Anglia, Norwich NR4 7TK, UK
* Correspondence: cynthia.whitchurch@quadram.ac.uk
Abstract: Recalcitrant chronic infections of implanted medical devices are often linked to the presence
of biofilms. The prevention and treatment of medical device-associated infections is a major source
of antibiotic use and driver of antimicrobial resistance globally. Lowering the incidence of infection
in patients that receive implanted medical devices could therefore significantly improve antibiotic
stewardship and reduce patient morbidity. Here we determined if modifying the design of an im-
plantable medical device to reduce bacterial attachment, impacted the incidence of device-associated
infections in clinical practice. Since the 1980s cochlear implants have provided long-term treatment
of sensorineural hearing deficiency in hundreds of thousands of patients world-wide. Nonetheless,
a relatively small number of devices are surgically explanted each year due to unresolvable infections.
Features associated with the accumulation of bacteria on the Cochlear™ Nucleus® CI24RE™ model
of cochlear implant devices were identified using both in vitro bacterial attachment assays and exam-
ination of explanted devices. Macro-scale design modifications that reduced bacterial attachment
in vitro were incorporated into the design of the CI500™ and Profile™ series of Nucleus implant.
Analyses of mandatory post-market vigilance data of 198,757 CI24RE and 123,084 CI500/Profile
series implantation surgeries revealed that these design modifications correlated with significantly
reduced infection rates. This study demonstrates that a design-centric approach aimed at mitigat-
ing bacterial attachment was a simple, and effective means of reducing infections associated with
Cochlear Nucleus devices. This approach is likely to be applicable to improving the designs of other
implantable medical devices to reduce device-associated infections.
Keywords: biofilm; medical device; infection; antibiotic resistance; AMR
1. Introduction
Over half of healthcare-associated infections can be attributed to implanted medical
devices occurring in 0.08–50% for the most common implant types depending on the
implant site, how long the device is implanted, patient comorbidities, or other risk factors
with the highest rates of infection associated with urinary and cardiac devices [1,2]. Device-
related infections are difficult and costly to treat due to lengthy antibiotic therapy and may
require surgical intervention and device removal in cases where the infection cannot be
resolved with antibiotics [1]. Recalcitrant chronic infections of implanted medical devices
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are often linked to the presence of persister cells [3] and surface-attached communities
of microorganisms called biofilms that have elevated resistances to antibiotics and the
immune system [4]. Almost immediately after a medical device is implanted it becomes
coated with a conditioning film comprised of host extracellular matrix, plasma proteins,
and platelets which can serve as receptors for colonizing bacteria and fungi which adhere
to the implant surface and establish biofilms [5].
The cochlear implant has been used to treat many forms of sensorineural hearing
deficiency in children as young as 5 months old to seniors in their 90s [6]. The component
that houses the receiver and stimulator circuitry is surgically implanted beneath the skin
behind the ear and secured in place [7]. The Cochlear™ Nucleus® device has two leads,
one of which contains an array of 22 electrodes that is inserted into the cochlea to stimulate
auditory nerves and a second lead which serves as a ground [7]. Following surgical
implantation the cochlear implant becomes encapsulated in fibrotic scar tissue [8].
Occasionally, days to even years later, chronic bacterial infections at the site of the
cochlear implant occur that are resistant to antimicrobial therapy [9]. These infections can
lead to tissue destruction, device dysfunction, and systemic dissemination of the pathogen.
In extreme cases, chronic and recurrent infections that are recalcitrant to therapeutic inter-
vention require device removal and subsequent re-implantation surgeries with associated
trauma [10]. While cochlear implant devices have proven to be highly successful, a rela-
tively small number are surgically removed each year due to unresolvable infections. It is
imperative that every effort should be made to reduce the incidence of device-associated
infections to minimize the risks and burdens to cochlear implant recipients.
The aim of this study is to assess if altering the macro-scale design of the Cochlear
Nucleus device, to ameliorate the potential for bacterial attachment, could reduce the inci-
dence of device-associated infections requiring surgical removal of the implant. Our aim
was to identify sites on the Cochlear Nucleus device which were prone to bacterial attach-
ment and use this data to inform modifications of the device design to mitigate bacterial
attachment. We utilized a combination of in vitro bacterial attachment assays and direct
examination of explanted devices to identify features of the Nucleus CI24RE™ model of
cochlear implant that were associated with bacterial attachment. We then modified the
design of these features in an attempt to mitigate bacterial attachment. The efficacy of
these design modifications was tested on prototype devices using our in vitro bacterial
attachment assay. The design modifications that were associated with reduction in bacte-
rial attachment in vitro were subsequently incorporated into the design of the Cochlear
Nucleus implant model CI500™ series (in use from 2010–2011) and the Profile™ series
(in use from 2014-present). A retrospective analysis of mandatory post-market vigi-
lance data was performed to determine the impact of these design modifications on
infection rates.
2. Materials and Methods
2.1. Identification of Bacterial Biomass on Cochlear Implant Devices In Vitro
Cochlear implant devices used in this study were provided by the manufacturer
Cochlear Limited, Sydney, Australia. Staphylococcus aureus is frequently isolated from
wound infections at the site of cochlear device implantation [10]. The S. aureus strain (CI494)
used in this study was isolated from the site of a cochlear implant-associated infection
and obtained from St Vincent’s Hospital, Melbourne, Australia. To identify features that
promoted bacterial attachment, in vitro bacterial attachment assays were performed on
ten CI24RE model Nucleus cochlear implant devices. S. aureus was allowed to attach to
cochlear implant devices suspended in nutrient broth for 48 h, washed to remove loosely
adherent bacteria, stained and visually inspected by fluorescence microscopy to determine
sites of bacterial attachment as follows. Sterile Cochlear Nucleus devices were coated for
24 h in fetal calf serum at 4 ◦C to provide a conditioning film for S. aureus attachment.
The devices were then suspended in 1:10,000 dilution of an overnight culture of S. aureus in
tryptic soya broth (TSB) and incubated with gentle stirring at 37 ◦C for 48 h with a change
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of media at 24 h. The devices were then washed three times in sterile phosphate buffered
saline (PBS) to remove loosely adherent bacteria. Attached S. aureus cells were stained with
the cell permeant DNA stain Syto 9 (2.5 µM; Thermo Fisher Scientific Australia, Scoresby,
VIC, Australia) and visualized with epifluorescence on an Olympus IX71 inverted research
microscope with a FViewII monochromatic camera (Olympus Australia, Notting Hill, VIC,
Australia) and AnalySIS Research acquisition software (version 2; Olympus Australia,
Notting Hill, VIC, Australia).
2.2. Cochlear Implant Device Design Modifications
Having identified features of the CI24RE device that were common sites of bacterial
attachment, design modifications were incorporated into the CI500/Profile series in an
attempt to mitigate bacterial attachment in these regions. These modifications included
ensuring clean cut silicone edges, removal of raised lettering, and the use of wider recesses
with smoother transitions. The same biocompatible materials used in the CI24RE devices
were used in the CI500/Profile devices. To determine if these design modifications reduced
bacterial attachment in vitro, bacterial attachment assays were performed as described
above with four CI500/Profile model prototypes and four CI24RE devices concurrently as
matched comparison controls.
2.3. Identification of Bacterial Biomass on Explanted Cochlear Implant Devices
The post-market vigilance process requires all explanted cochlear implant devices to
be returned to the manufacturer for mechanical and electrical assessment. This process
standardly involves sterilization and removal of all biological material and is therefore not
compatible with determining sites of bacterial biomass. We were interested in determining
if and where bacterial biomass was located on devices that had been explanted due to
infection or electro-mechanical failure. To achieve this, a small number of devices were
processed immediately after explant as follows. Four CI24RE devices from patients with
unresolvable infection at the cochlear implant site and two CI24RE devices from patients
with electro-mechanical failures of the cochlear implant device and no clinical evidence
of infection were surgically removed at the Washington University School of Medicine in
St Louis, USA and placed immediately into sterile jars containing a formalin/ethanol
solution (50% (v/v) of a 10% solution of neutral buffered formalin (NBF): 45% (v/v) absolute
ethanol and 5% (v/v) glycerol). The explanted devices were then couriered to our laboratory
in Sydney, Australia for analysis of bacterial biomass by fluorescence in situ hybridization
(FISH). The oligonucleotide FISH probe used in this study (synthesized by Integrated DNA
Technologies, Inc. Singapore 117610, Republic of Singapore) was the general eubacterial
probe EUB-388-Cy3 (5′-/5Cy3/GCT GCC TCC CGT AGG AGT3′) [11].
Detection of Gram-negative bacterial biomass by FISH was performed as follows.
Formalin/ethanol fixed devices were passed through an ethanol dehydration procedure
(50% (v/v), 80% (v/v), 95% (v/v) ethanol, 30 min each) and allowed to dry at room
temperature. For general detection of Gram-negative bacteria, samples were hybridized
with the 16S rRNA oligonucleotide probe (EUB-388-Cy3) as follows. Hybridization buffer
(0.9 M NaCl, 0.01% (v/v) SDS, 20 mM Tris-HCl pH 7.2, formamide 20% (v/v)) containing
10 ng/µL of FISH probe was applied to the samples before placing them in a humidified
chamber at 46 ◦C for 3 h. Samples were then de-stained with a wash buffer (20 mM
Tris-HCl pH 7.2, 0.01% (v/v) SDS, 40 mM NaCl, 5 mM ETDA) for 15 min at 46 ◦C in a
humidified chamber. After washing with MilliQ water, samples were air dried at room
temperature. Samples were imaged using a DeltaVision Elite inverted research microscope
with InsightSSI illumination, SoftWorX acquisition software, fitted with a scientific CMOS
15-bit camera (pco.edge, PCO AG, Kelheim, Germany).
The Gram-negative FISH staining procedure does not enable penetration of the FISH-
probe into Gram-positive bacteria due to their thick cell-walls. Therefore, after imaging
for Gram-negative bacteria, devices were then treated with 10 µg/mL of Proteinase K and
incubated at 37 ◦C for 1 h. The reaction was then stopped with ice-cold PBS. This Proteinase
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K step removes Gram-negative bacteria due to destruction of the thin Gram-negative cell
wall and allows the FISH probe to enter Gram-positive cells so that only Gram-positive
bacterial biomass is visualized. Hybridization of the 16S rRNA oligonucleotide probe
(EUB-388-Cy3) and fluorescence microscopy were performed as described for detection of
Gram-negative bacteria. Following completion of the microscopic assessment of bacterial
burden, the devices were returned to the manufacturer to enter the routine returned devices
assessment process.
2.4. Analysis of Outcomes in Clinical Practice
Mandatory post-market surveillance and vigilance data were collected according to
regional-specific regulations. This ensures a high level of compliance and reporting of
outcomes associated with all Cochlear Nucleus implant surgeries. Post-market surveillance
and vigilance data were obtained for 198,757 CI24RE implantation surgeries from 2005 until
2020, 29,895 CI500 implantation surgeries from 2010–2011 and 93,189 Profile implantation
surgeries from 2014 until 2020. Complaints and issues reported for implanted Cochlear
Nucleus devices before (CI24RE series) and after (CI500/Profile series) design modifications
were compared, and statistical analyses performed to assess differences in the reported rates
of unresolvable infections leading to device removal. Specifically, post-market vigilance
data were examined for reports of infections that were recalcitrant to antibiotic therapy
and required surgical removal of the device. These were classified as “infections leading
to explant”. As both the CI500 and Profile series devices have identical external designs
and materials, in this study we refer to both of these devices collectively as “CI500/Profile”
unless the data refers to only the CI500 or the Profile separately.
2.5. Statistical Analyses
Statistical analyses were performed using Minitab software [12]. Actuarial analyses
were performed with 12-month analysis intervals since implantation and the survival
probability is presented with 95% two-sided confidence intervals. Survival curves were
compared with Log-Rank and Wilcoxon tests.
3. Results
We first performed in vitro bacterial attachment assays to identify features of the
Cochlear Nucleus CI24RE model that routinely acquired higher bacterial biomass compared
to other regions of the device. Features that were associated with higher levels of bacterial
attachment in vitro included rough silicone edges such as those at the edge of the magnet
pocket and abutting the extracochlear electrode (ECE) plate; the metal surface and raised
lettering of the ECE plate; and regions with deep recesses and steep sides (Figure 1A).
Flat areas of silicone had fewest attached bacteria (Figure 1A).
We also examined if and where bacterial biomass was located on CI24RE devices
explanted due to unresolvable infections. We found that bacterial biomass was located on
the ECE plate (silicone edges and raised lettering) in all four CI24RE devices associated
with infections and on the silicone edges of the magnet pocket in three of the four devices
(Figure 1B). Therefore, there appeared to be bacterial biomass and biofilms situated in the
same regions of CI24RE devices that had been surgically removed due to infection as had
been identified in our in vitro assay as areas to which bacteria had a propensity to attach.
There was little to no bacteria present on the devices that had been surgically removed
due to electro-mechanical failure, indicating that the presence of bacterial biomass on the
devices associated with infections were unlikely to be an artefact of the staining procedure.
Having identified features of the CI24RE cochlear implant that appeared to promote
bacterial attachment which could potentially lead to unresolvable infections, we mod-
ified some of these features of the CI500/Profile series in an attempt to mitigate this.
We performed in vitro bacterial attachment assays of CI500/Profile series prototypes incor-
porating these design modifications. Visual inspection of these prototype devices showed
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reduced levels of bacterial attachment in these regions compared to CI24RE devices assayed
concurrently (Figure 2).
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Figure 1. Imaging of bacterial biomass on cochlear implant devices. (A) Attachment of S. aureus to
CI24RE devices in in vitro assays visualized with Syto-9 (gree ) stain. (B) CI24RE devices explanted
due to infection visualized using a general eubacterial FISH probe (green). Imaged regions are as
follows: magnet pocket edge, silicone abutting extracochlear electrode (ECE), ECE lettering, ECE flat
metal, deep recesses, or flat silicone. Scale bar is 100 µm for all images. Images are representative of
(A) ten or (B) four devices.
The design modifications that reduced bacterial attachment in vitro were incorpo-
rated into the CI500 series of the Nucleus cochlear implant available from 2010–2011 and
the Profile model of Nucleus cochlear implant available from 2014-present. Post-market
vigilance data of 198,757 CI24RE and 123,084 CI500/Profil series implantation surgeries
from 2005–2020 was examined for reports of infections that were recalcitrant to therapy
and required surgical removal of the device. Analysis of this infection data revealed
that patients who received the CI500/Profile model had significantly lower overall rates
of infection leading to device explant compared to those that had received the CI24RE
device (Figure 3A; p-value of <0.0005 for Log-Rank and Wilcoxon tests demonstrating
statistically significant differences). To assess if the differences in these infection rates are
due to alterations in the implanted Nuclear device design rather than other influencing
factors such as changes in clinical sterility, surgeon training and guidelines, and antibiotic
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availability and usage practices, we compared infection data of patients who received
either the CI24RE or CI500/Profile series across the same time periods. Data were obtained
for patients who received either the CI24RE (142,439) or CI500/Profile series (123,084)
from 2010–2020 (Figure 3B) and for patients who received either the CI24RE (80,845)
or Profile (93,189) cochlear implant device from 2014–2020 (Figure 3C). Analysis of this data
showed that the rates of infection leading to device explant during the same time periods
was significantly lower for the CI500/Profile series than for the CI24RE Nucleus model
(Figure 3B,C; p-values of <0.0005 for Log-Rank and Wilcoxon tests demonstrating statisti-
cally significant differences).




Figure 2. Bacterial attachment is decreased on CI500/Profile series cochlear devices. Attachment of S. aureus to prototype 
CI500/Profile series devices in in vitro assays visualized with Syto-9 (green) stain. Imaged regions were the magnet pocket 
edge, deep recesses or extracochlear electrode (ECE) flat metal. All regions showed very little bacterial attachment and no 
bacterial aggregates were observed. Images of CI24RE devices imaged at the same time as these CI500/Profile images were 
identical to those shown in Figure 1A. Scale bar is 100 μm. Images are representative of four devices. 
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Figure 2. Bacterial attachment is decreased on CI500/Profile series cochlear devices. Attachment of
S. aureus to prototype CI500/Profile series devices in in vitro assays visualized with Syto-9 (green)
stain. Imaged regio s we e the magnet pocket edge, deep recesses or extracochlear electrode (ECE)
flat metal. All regions showed very little bacterial attachment and no bacterial aggregates were
observed. Images of CI24RE devices imaged at the same time as these CI500/Profile images were
identical to those shown in Figure 1A. Scale bar is 100 µm. Images are representative of four devices.
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information on the implant recipients was performed. The clinical indications for use
are the same for both the CI24RE and CI500/Profile devices and both devices hav been
implanted in over 100 cou tri s. The infection rate data for the implant per ods 2010–2020
(Figure 3B) and 2014–202 (Figure 3C) were viewed for countries in each of the Americas,
Europe, and Asia-Pacific regions as well s the G7 countries. In all geograp ical regions,
the rates of infection leading to explant were significantly reduced for the CI500/Profile
series compared to the CI24RE (Tables 1 and 2).
The data were also analyzed according to recipient gender and age. For the devices
implanted in 2010–2020 (Figure 3B), the proportion of pediatric recipients of the CI24RE
device is 56.2% while the proportion of pediatric infections with the CI24RE is 57.4%.
The proportion of pediatric recipients of the CI500/Profile is 40.0% while the proportion
of pediatric infections with the CI500/Profile is 36.3%. For this period, the proportion of
female recipients of the CI24RE is 47.3% while the proportion of female infections with the
CI24RE is 47.7% and the proportion of emale recipients of the CI500/Profile is 48.3% while
the proportion of female infection with the CI500/Profile is 46.5%.
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information on the implant recipients was performed. The clinical indications for use are 
the same for both the CI24RE and CI500/Profile devices and both devices have been 
implanted in over 100 countries. The infection rate data for the implant periods 2010–2020 
(Figure 3B) and 2014–202 (Figure 3C) were reviewed for countries in each of the Americas, 
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 Infection Rate 1 Proportion 2 Infection Rate 1 Proportion 2 Fold Change 
Americas 0.82% 32% 0.33% 40% 2.5 
Asia Pacific 0.44% 37% 0.27% 18% 1.6 
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Figure . lative percentage of infections leading to explant per year of implantation for C chlear
Nuc us devic s before (CI24RE) and after (CI500/Profile) design m difications. Cumulative per-
centages of infections leading to explant per year since device implantation for (A) CI24RE (devices
implanted from 2005–2020) or CI500/Profile (devices implanted from 2010–2020); (B) CI24RE or
CI500/Profile (devices implanted from 2010–2020); (C) CI24RE or Profile (devices implanted from
2014–2020). Data are presented as the cumulative failure percentage with 95% confidence intervals.
For (A) CI24RE (n = 198,757) or CI500/Profile (n = 123,084), (B) CI24RE (n = 142,439) or CI500/Profile
(n = 123,084) and (C) CI24RE (n = 80,845) or Profile (n = 93,189).
Table 1. Percentage of infections leading to explant by geographical region (2010–2020).
Region CI24RE CI500/Profile
Infection Rate 1 Proportion 2 Infection Rate 1 Proportion 2 Fold Change
Americas 0.82% 32% 0.33% 40% 2.5
Asia Pacific 0.44% 37% 0.27% 18% 1.6
Europe/Middle
East/Africa 0.65% 31% 0.23% 42% 2.8
G7 countries 0.95% 33% 0.32% 64% 3
1 Infection leading to explant; 2 proportion of total devices of this model implanted in this period.
For the devices implanted in 2014–2020 (Figure 3C), the proportion of pediatric recipi-
ents of the CI24RE is 61.3% while the proportion of pediatric infections with the CI24RE is
60.5%. The proportion of pediatric recipients of the CI500/Profile is 39.6% while the propor-
tion of pediatric infections with the CI500/Profile is 31.7%. For this period, the proportion
of female recipients of the CI24RE is 46.3% while the proportion of female infections with
the CI24RE is 45.5% and the proportion of female recipients of the CI500/Profile is 47.7%
while the proportion of female infections with the CI500/Profile is 45.7%.
Microorganisms 2021, 9, 1809 8 of 10
Table 2. Percentage of infections leading to explant by geographical region (2014–2020).
Region CI24RE Profile
Infection Rate 1 Proportion 2 Infection Rate 1 Proportion 2 Fold Change
Americas 0.71% 28% 0.28% 38% 2.5
Asia Pacific 0.33% 47% 0.25% 19% 1.3
Europe/Middle
East/Africa 0.55% 25% 0.21% 43% 2.6
G7 countries 0.81% 24% 0.30% 63% 2.7
1 Infection leading to explant; 2 proportion of total devices of this model implanted in this period.
In general, the infection rate proportion follows the age and gender demographic
proportions except for the pediatric infection rate for CI500/Profile which is lower than the
proportion of recipients. As the proportion of pediatric recipients for the CI500/Profile is
less than 50% this will to some extent counter the lower infection rate overall. Despite this
effect, the lower infection rate of CI500/Profile compared to CI24RE is significant.
These analyses indicate that the significant improvement in rates of infections leading
to explant of the CI500/Profile compared to the CI24RE series of Nucleus cochlear implants
is likely to be due to the differences in device design, and not due to other demographic
factors associated with geographical region, age, or gender.
4. Discussion
Infections associated with implanted medical devices are often recalcitrant to an-
timicrobial therapy due to the presence of biofilms [4] and persister cells [3] that have
elevated resistances to antibiotics and immune clearance. The overuse of antibiotics to treat
device-associated infections is associated with increasing levels of antimicrobial resistance
among bacterial pathogens [13]. Therefore, lowering the incidence of infection in patients
who receive implanted medical devices will not only result in a reduction of the potential
risks and burdens to implant recipients but may also result in reduced antibiotic usage,
which is an important consideration for antibiotic stewardship in the fight against antimi-
crobial resistance. Approaches aimed at preventing bacterial colonization and subsequent
infections associated with implanted medical devices largely focus on modifications of the
device at the nanoscale. These include alteration of surface properties such as topography,
roughness, and hydrophobicity; or involve functionalized surfaces that elute antibiotics;
or that incorporate bactericidal moieties or anti-adhesive polymers [14,15]. However, to-
date, little consideration has been given to the contribution of device design features at the
macro-scale in promoting or inhibiting the propensity of bacteria to initiate attachment to
implanted medical devices.
In this study we utilized direct microscopic examination of Cochlear Nucleus implant
devices to identify physical features that may promote bacterial attachment and subsequent
biofilm formation. We found that modification of the design of the Cochlear Nucleus
implant device, while utilizing the same biocompatible materials, was able to mitigate
bacterial attachment to these features in vitro. Specifically, we implemented modifications
to ensure clean cut silicone edges, removal of raised implant identification lettering, and use
of wider recesses with smoother transitions which proved to be effective in mitigating
bacterial attachment in vitro. Importantly, these design modifications were incorporated in
the CI500/Profile series of Cochlear Nucleus implant and were associated with a significant
reduction in the rates of reports of infections leading to explant in patients who received
the CI500/Profile devices relative to CI24RE recipients (Figure 3A). Comparison of data
of reports of infections leading to explant in patients who received either the CI24RE or
the CI500 or Profile devices over the same time periods and in the same regions, suggests
that the observed reduction in infection rates are likely to be associated with the design
changes implemented, and not to other factors such as patient demographics or changes in
clinical procedures in different geographical locations (Figure 3B,C, Tables 1 and 2).
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To our knowledge this is the first research report addressing the consideration of
macro-scale device design as a means of reducing the incidence of device-associated
infections. Many other silicone and metal-based implants, e.g., defibrillators, heart pumps,
catheters, surgical reconstructive components, and prosthetics have intricate design features
that may be sites for preferential bacterial attachment [16]. It is therefore worth considering
if physical features of other implanted medical devices may also be amenable to design
modifications that will reduce the propensity for bacterial attachment and limit subsequent
device-associated infections. This would limit the need for extended antibiotic treatments
and reduce the costs, risks, and burdens to recipients of implanted medical devices and
health-care systems.
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